9,816 Shares in Bioventus Inc. (NYSE:BVS) Acquired by Quantbot Technologies LP

Quantbot Technologies LP acquired a new stake in Bioventus Inc. (NYSE:BVS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 9,816 shares of the company’s stock, valued at approximately $103,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp grew its position in shares of Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after acquiring an additional 189,216 shares during the last quarter. JPMorgan Chase & Co. grew its position in Bioventus by 228.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after purchasing an additional 176,442 shares during the last quarter. FMR LLC increased its stake in Bioventus by 21,256.6% in the third quarter. FMR LLC now owns 166,795 shares of the company’s stock valued at $1,993,000 after purchasing an additional 166,014 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Bioventus by 38.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock valued at $4,662,000 after buying an additional 109,359 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of Bioventus during the third quarter worth about $1,011,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Bioventus news, CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the transaction, the chief executive officer now owns 64,964 shares of the company’s stock, valued at $591,172.40. This trade represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,161 shares of company stock valued at $436,364 over the last 90 days. Insiders own 32.90% of the company’s stock.

Analyst Upgrades and Downgrades

BVS has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Up 1.3 %

Shares of NYSE BVS opened at $9.15 on Tuesday. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38. The company has a market capitalization of $749.79 million, a PE ratio of -15.00 and a beta of 0.86. The firm’s 50-day moving average is $10.05 and its two-hundred day moving average is $10.97.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.